背景:冠心病是全球死亡的主要原因之一。二级预防至关重要,因为它降低了进一步冠状动脉事件的风险。移动健康(mHealth)技术可以成为改善生活方式的有用工具。
目的:本研究旨在评估mHealth干预对接受经皮冠状动脉介入治疗的冠心病患者的影响。改善饮食方面的生活方式,身体活动,和吸烟;健康生活方式的知识水平和心血管危险因素(CVRF)的控制;以及治疗依从性和生活质量进行了分析。
方法:这是一项随机对照试验,平行组设计以1:1分配给涉及智能手机应用程序的干预(mHealth组)或标准医疗保健(对照组)。该应用程序用于设定目标,使用测量和记录对生活方式和CVRF进行自我监测,教育人们在屏幕上获得有关健康生活方式和坚持治疗的信息,并通过反馈有关成就和需要改进的方面给予激励。两组均在9个月后进行评估。主要结果变量是坚持地中海饮食,食物消耗的频率,患者报告的身体活动,吸烟,健康生活方式的知识和CVRF的控制,坚持治疗,生活质量,幸福,和满意度。
结果:该研究分析了128名患者,mHealth组67例,对照组61例;大多数为男性(92/128,71.9%),平均年龄为59.49(SD8.97)岁。与对照组相比,在坚持地中海饮食方面,mHealth组观察到了显着改善(平均11.83,SD1.74点与平均10.14,SD2.02点;P<.001),食物消费的频率,患者报告的身体活动(平均619.14,SD318.21分钟/周与平均471.70,SD261.43分钟/周;P=.007),戒烟(25/67,75%vs11/61,42%;P=0.01),健康生活方式的知识水平和CVRF的控制(平均118.70,SD2.65点与平均111.25,SD9.05点;P<.001),和生活质量的物理成分12项简表调查(SF-12;平均45.80,SD10.79点与平均41.40,SD10.78点;P=.02)。mHealth组的总体满意度较高(平均48.22,SD3.89与平均46.00,SD4.82分;P=.002),应用程序满意度和可用性较高(50分中的平均44.38,SD6.18,100分中的平均95.22,SD7.37)。
结论:EVITE应用程序在坚持地中海饮食方面有效改善患者的生活方式,健康食品消费的频率,身体活动,戒烟,健康生活方式和控制CVRF的知识,生活质量,和总体满意度。应用程序满意度和可用性非常好。
背景:Clinicaltrials.govNCT04118504;https://clinicaltrials.gov/study/NCT04118504。
BACKGROUND: Coronary heart disease is one of the leading causes of mortality worldwide. Secondary prevention is essential, as it reduces the risk of further coronary events. Mobile health (mHealth) technology could become a useful tool to improve lifestyles.
OBJECTIVE: This study aimed to evaluate the effect of an mHealth intervention on people with coronary heart disease who received percutaneous coronary intervention. Improvements in lifestyle regarding diet, physical activity, and smoking; level of knowledge of a healthy lifestyle and the control of cardiovascular risk factors (CVRFs); and therapeutic adherence and quality of life were analyzed.
METHODS: This was a randomized controlled trial with a parallel group design assigned 1:1 to either an intervention involving a smartphone app (mHealth group) or to standard health care (control group). The app was used for setting aims, the self-monitoring of lifestyle and CVRFs using measurements and records, educating people with access to information on their screens about healthy lifestyles and adhering to treatment, and giving motivation through feedback about achievements and aspects to improve. Both groups were assessed after 9 months. The primary outcome variables were adherence to the Mediterranean diet, frequency of food consumed, patient-reported physical activity, smoking, knowledge of healthy lifestyles and the control of CVRFs, adherence to treatment, quality of life, well-being, and satisfaction.
RESULTS: The study analyzed 128 patients, 67 in the mHealth group and 61 in the control group; most were male (92/128, 71.9%), with a mean age of 59.49 (SD 8.97) years. Significant improvements were observed in the mHealth group compared with the control group regarding adherence to the Mediterranean diet (mean 11.83, SD 1.74 points vs mean 10.14, SD 2.02 points; P<.001), frequency of food consumption, patient-reported physical activity (mean 619.14, SD 318.21 min/week vs mean 471.70, SD 261.43 min/week; P=.007), giving up smoking (25/67, 75% vs 11/61, 42%; P=.01), level of knowledge of healthy lifestyles and the control of CVRFs (mean 118.70, SD 2.65 points vs mean 111.25, SD 9.05 points; P<.001), and the physical component of the quality of life 12-item Short Form survey (SF-12; mean 45.80, SD 10.79 points vs mean 41.40, SD 10.78 points; P=.02). Overall satisfaction was higher in the mHealth group (mean 48.22, SD 3.89 vs mean 46.00, SD 4.82 points; P=.002) and app satisfaction and usability were high (mean 44.38, SD 6.18 out of 50 points and mean 95.22, SD 7.37 out of 100).
CONCLUSIONS: The EVITE app was effective in improving the lifestyle of patients in terms of adherence to the Mediterranean diet, frequency of healthy food consumption, physical activity, giving up smoking, knowledge of healthy lifestyles and controlling CVRFs, quality of life, and overall satisfaction. The app satisfaction and usability were excellent.
BACKGROUND: Clinicaltrials.gov NCT04118504; https://clinicaltrials.gov/study/NCT04118504.